Liu M.,Shandong Jiaotong Hospital |
Lu Y.,Shandong Jiaotong Hospital |
Huan Y.,Shandong Jiaotong Hospital |
Ge R.,Cell Rescue Center |
And 7 more authors.
Journal of Clinical Rehabilitative Tissue Engineering Research | Year: 2011
BACKGROUND: There is no clear standard for curing autism, and the effect of rehabilitation treatment is not satisfied. OBJECTIVE: To evaluate the safety and efficacy of cord blood mononuclear cells (MNCs) and umbilical cord mesenchymal stem cells (MSCs) in treating autistic children. METHODS: Thirty-seven children with autism were divided into MNCs treatment (MNCs plus rehabilitation treatment), MNCs combined with MSCs treatment (MNCs combined with MSCs plus rehabilitation treatment) and control (rehabilitation treatment alone) groups. Related laboratory examinations were performed for each group before treatment, 1, 2 and 6 months after treatment to observe adverse effects. Childhood Autism Rating Scale and Aberrant Behavior Checklist were employed to assess the children of autism. RESULTS AND CONCLUSION: There was no statistical difference between MNCs treatment group and MNCs combined with MSCs treatment group in laboratory examinations at each time point, and no adverse effects were observed in two groups. Childhood Autism Rating Scale and Aberrant Behavior Checklist showed that three treatment presented efficacy, but the MNCs combined with MSCs treatment group was the best, followed by MNCs treatment group, and then control group.